Covid-19 Research

Review Article

Role of Cyclooxygenase-2 Inhibitors in Animal Models of Epilepsy: A Systematic Review

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Review Article
Subject Medicine Group
OCLC JBRES Record
Somia S* and Muhammad FN
Issue: Volume6-Issue7
Pages: 1006-1015
Received: 2025-07-15
Accepted: 2025-07-31
Published: 2025-07-31

Abstract

Background: The presence of recurrent seizures characterizes epilepsy, which is defined as a chronic disorder of the nervous system. It has recently been suggested that COX-2 inhibitors may offer protective neurotherapeutic effects while simultaneously controlling seizures. The animal model is an important tool for assessing these interventions.

Objectives: This review assessed the literature regarding COX-2 inhibitors in animal models of epilepsy, focusing on their efficacy both in terms of seizure control and neuroprotection. As an effort to inform future research and clinical guidelines, the review collates information on known study gaps, particularly those related to standardized dosing and long-term outcomes.

Methodology: A comprehensive literature search was conducted on Google Scholar, PubMed, Scopus, and Web of Science using the following keywords: “Epilepsy,” “Seizure,” “Neuroprotection,” “Seizure Reduction,” “Inflammatory mediators,” and “COX-2 Inhibitors.” Out of 400 initially reviewed articles, 20 original research articles matched the selection criteria. These studies were conducted in animal models of epilepsy aimed at seizure reduction and neuroprotection through COX-2 inhibitors, and the articles were available in open-access full text. Restricted-access articles, review articles, clinical trials, and those with full-text unpublished data were not included. The risk of bias in the selected studies was assessed with SYRCLE’s tool.

Results: COX-2 inhibitors have been shown to decrease seizures and provide neuroprotection with varying success across many animal models. COX-2 inhibitors showed promise as neuroprotective agents, and their efficacy in seizure reduction has a considerable range. This systematic review highlights the considerable gaps concerning optimized dosage, efficacy duration, and comparative effectiveness across different epilepsy models.

Conclusion: COX-2 inhibitors demonstrated promise in seizure attenuation along with neuroprotection. There are important gaps regarding standardization of treatment protocols, evaluation of chronic impact, and mechanism understanding in different types of epilepsy models, which require focus from further study.

FullText HTML FullText PDF DOI: 10.37871/jbres2156 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2025 Somia S, et al., Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Somia S, Muhammad FN. Role of Cyclooxygenase-2 Inhibitors in Animal Models of Epilepsy: A Systematic Review. J Biomed Res Environ Sci. 2025 Jul 31; 6(7): 1006-1015. doi: 10.37871/jbres2156, Article ID: JBRES2156, Available at: https://www.jelsciences.com/articles/jbres2156.pdf

Subject area(s)

Brain DisordersNeurologyPharmacology

References

  1. Dhir A. An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders. Expert Opin Investig Drugs. 2019 Feb;28(2):191-205. doi: 10.1080/13543784.2019.1557147. Epub 2018 Dec 13. PMID: 30521407.
  2. Arend J, Kegler A, Caprara ALF, Almeida C, Gabbi P, Pascotini ET, de Freitas LAV, Miraglia C, Bertazzo TL, Palma R, Arceno P, Duarte MMMF, Furian AF, Oliveira MS, Royes LFF, Mathern GW, Fighera MR. Depressive, inflammatory, and metabolic factors associated with cognitive impairment in patients with epilepsy. Epilepsy Behav. 2018 Sep;86:49-57. doi: 10.1016/j.yebeh.2018.07.007. Epub 2018 Aug 2. PMID: 30077908.
  3. Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R. Cyclooxygenase-2 in epilepsy. Epilepsia. 2014 Jan;55(1):17-25. doi: 10.1111/epi.12461. Epub 2013 Nov 8. PMID: 24446952; PMCID: PMC3956447.
  4. Trinka E, Kwan P, Lee B, Dash A. Epilepsy in Asia: Disease burden, management barriers, and challenges. Epilepsia. 2019 Mar;60 Suppl 1:7-21. doi: 10.1111/epi.14458. Epub 2018 Jun 28. PMID: 29953579.
  5. Javaid S, Alqahtani F, Ashraf W, Anjum SMM, Rasool MF, Ahmad T, Alasmari F, Alasmari AF, Alqarni SA, Imran I. Tiagabine suppresses pentylenetetrazole-induced seizures in mice and improves behavioral and cognitive parameters by modulating BDNF/TrkB expression and neuroinflammatory markers. Biomed Pharmacother. 2023 Apr;160:114406. doi: 10.1016/j.biopha.2023.114406. Epub 2023 Feb 13. PMID: 36791567.
  6. Radu BM, Epureanu FB, Radu M, Fabene PF, Bertini G. Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy. Epilepsy Res. 2017 Mar;131:15-27. doi: 10.1016/j.eplepsyres.2017.02.003. Epub 2017 Feb 9. PMID: 28212985.
  7. Falco-Walter J. Epilepsy-Definition, Classification, Pathophysiology, and Epidemiology. Semin Neurol. 2020 Dec;40(6):617-623. doi: 10.1055/s-0040-1718719. Epub 2020 Nov 5. PMID: 33155183.
  8. Ułamek-Kozioł M, Czuczwar SJ, Januszewski S, Pluta R. Ketogenic diet and epilepsy. Nutrients. 2019;11(10):2510.
  9. Shimada T, Yamagata K. Pentylenetetrazole-Induced Kindling Mouse Model. J Vis Exp. 2018 Jun 12;(136):56573. doi: 10.3791/56573. PMID: 29985308; PMCID: PMC6101698.
  10. Ahlatcı A, Yıldızhan K, Tülüce Y, Bektaş M. Valproic Acid Attenuated PTZ-induced Oxidative Stress, Inflammation, and Apoptosis in the SH-SY5Y Cells via Modulating the TRPM2 Channel. Neurotox Res. 2022 Dec;40(6):1979-1988. doi: 10.1007/s12640-022-00622-3. Epub 2022 Dec 20. PMID: 36536269.
  11. Vezzani A, Balosso S, Ravizza T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019 Aug;15(8):459-472. doi: 10.1038/s41582-019-0217-x. Epub 2019 Jul 1. PMID: 31263255.
  12. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014 Mar 26;14:43. doi: 10.1186/1471-2288-14-43. PMID: 24667063; PMCID: PMC4230647.
  13. Jiang J, Yu Y, Kinjo ER, Du Y, Nguyen HP, Dingledine R. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology. 2019 May 1;149:149-160. doi: 10.1016/j.neuropharm.2019.02.011. Epub 2019 Feb 11. PMID: 30763657; PMCID: PMC6486887.
  14. Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-6. doi: 10.1073/pnas.1218498110. Epub 2013 Feb 11. PMID: 23401547; PMCID: PMC3587237.
  15. Royero PX, Higa GSV, Kostecki DS, Dos Santos BA, Almeida C, Andrade KA, Kinjo ER, Kihara AH. Ryanodine receptors drive neuronal loss and regulate synaptic proteins during epileptogenesis. Exp Neurol. 2020 May;327:113213. doi: 10.1016/j.expneurol.2020.113213. Epub 2020 Jan 24. PMID: 31987836.
  16. Yu Y, Jiang J. COX-2/PGE2 axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures. Epilepsia Open. 2020 Jun 9;5(3):418-431. doi: 10.1002/epi4.12409. PMID: 32913950; PMCID: PMC7469770.
  17. Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiol Dis. 2015 Apr;76:126-136. doi: 10.1016/j.nbd.2014.12.032. Epub 2015 Jan 17. PMID: 25600211; PMCID: PMC4408774.
  18. Nagib MM, Yu Y, Jiang J. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Pharmacol Ther.. 2020;209:107504.
  19. Li L, Sluter MN, Yu Y, Jiang J. Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy. Pharmacol Res. 2021;163:105238.
  20. Zandieh A, Maleki F, Hajimirzabeigi A, Zandieh B, Khalilzadeh O, Dehpour AR. Anticonvulsant effect of celecoxib on pentylenetetrazole-induced convulsion: Modulation by NO pathway. Acta Neurobiol Exp (Wars). 2010;70(4):390-7. doi: 10.55782/ane-2010-1811. PMID: 21196947.
  21. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S, Panikashvili D, Shohami E, Jansen SA, Narayan RK, Strauss KI. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery. 2005 Mar;56(3):590-604. doi: 10.1227/01.neu.0000154060.14900.8f. PMID: 15730585; PMCID: PMC1513642.
  22. Mareš J, Pometlová M, Deykun K, Krýsl D, Rokyta R. An isolated epileptic seizure elicits learning impairment which could be prevented by melatonin. Epilepsy Behav. 2012 Mar;23(3):199-204. doi: 10.1016/j.yebeh.2011.11.018. Epub 2012 Feb 16. PMID: 22341963.
  23. Dhir A, Naidu PS, Kulkarni SK. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Dec;16(8):691-7. doi: 10.1016/j.seizure.2007.05.016. Epub 2007 Jul 2. PMID: 17604186.
  24. Clossen BL, Reddy DS. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1519-1538. doi: 10.1016/j.bbadis.2017.02.003. Epub 2017 Feb 5. PMID: 28179120; PMCID: PMC5474195.
  25. Claycomb RJ, Hewett SJ, Hewett JA. Prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition. Epilepsia. 2011 Feb;52(2):273-83. doi: 10.1111/j.1528-1167.2010.02889.x. Epub 2011 Jan 10. PMID: 21219314; PMCID: PMC4445939.
  26. Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, Speigel I, Rojas A, Lelutiu N, Dingledine R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54. doi: 10.1073/pnas.1120195109. Epub 2012 Feb 8. PMID: 22323596; PMCID: PMC3286971.
  27. Rawat V, Eastman CL, Amaradhi R, Banik A, Fender JS, Dingledine RJ, D'Ambrosio R, Ganesh T. Temporal Expression of Neuroinflammatory and Oxidative Stress Markers and Prostaglandin E2 Receptor EP2 Antagonist Effect in a Rat Model of Epileptogenesis. ACS Pharmacol Transl Sci. 2022 Dec 8;6(1):128-138. doi: 10.1021/acsptsci.2c00189. PMID: 36654746; PMCID: PMC9841781.
  28. Polascheck N, Bankstahl M, Löscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol. 2010 Jul;224(1):219-33. doi: 10.1016/j.expneurol.2010.03.014. Epub 2010 Mar 29. PMID: 20353773.
  29. Holtman L, van Vliet EA, Edelbroek PM, Aronica E, Gorter JA. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res. 2010 Sep;91(1):49-56. doi: 10.1016/j.eplepsyres.2010.06.011. PMID: 20643531.
  30. Akula KK, Dhir A, Kulkarni SK. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Res. 2008 Jan;78(1):60-70. doi: 10.1016/j.eplepsyres.2007.10.008. Epub 2007 Dec 3. PMID: 18054463.
  31. Alsaegh H, Eweis H, Kamal F, Alrafiah A. Celecoxib Decrease Seizures Susceptibility in a Rat Model of Inflammation by Inhibiting HMGB1 Translocation. Pharmaceuticals (Basel). 2021 Apr 19;14(4):380. doi: 10.3390/ph14040380. PMID: 33921725; PMCID: PMC8073600.
  32. Kunz T, Oliw EH. Nimesulide aggravates kainic acid-induced seizures in the rat. Pharmacol Toxicol. 2001 May;88(5):271-6. doi: 10.1034/j.1600-0773.2001.d01-116.x. PMID: 11393589.
  33. Toscano CD, Ueda Y, Tomita YA, Vicini S, Bosetti F. Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res Bull. 2008 Mar 28;75(5):598-609. doi: 10.1016/j.brainresbull.2007.10.004. Epub 2007 Nov 9. PMID: 18355636; PMCID: PMC2423277.
  34. Zhou L, Zhou L, Su LD, Cao SL, Xie YJ, Wang N, Shao CY, Wang YN, Zhou JH, Cowell JK, Shen Y. Celecoxib Ameliorates Seizure Susceptibility in Autosomal Dominant Lateral Temporal Epilepsy. J Neurosci. 2018 Mar 28;38(13):3346-3357. doi: 10.1523/JNEUROSCI.3245-17.2018. Epub 2018 Feb 28. PMID: 29491011; PMCID: PMC5884462.
  35. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999 Oct 2;843(1-2):118-29. doi: 10.1016/s0006-8993(99)01797-7. PMID: 10528118.
  36. Candelario-Jalil E, Ajamieh HH, Sam S, Martínez G, León Fernández OS. Nimesulide limits kainate-induced oxidative damage in the rat hippocampus. Eur J Pharmacol. 2000 Mar 3;390(3):295-8. doi: 10.1016/s0014-2999(99)00908-5. PMID: 10708736.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership